

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM688814

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ORIGIN BIOSCIENCES, INC.		11/17/2021	Corporation: DELAWARE
BRIDGEBIO PHARMA, INC.		11/17/2021	Corporation: DELAWARE
QED THERAPEUTICS, INC.		11/17/2021	Corporation: DELAWARE
EIDOS THERAPEUTICS, INC.		11/17/2021	Corporation: DELAWARE
ADRENAS THERAPEUTICS, INC.		11/17/2021	Corporation: DELAWARE
PHOENIX TISSUE REPAIR, INC.		11/17/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	U.S. Bank National Association		
Street Address:	1 Federal St.		
City:	Boston		
State/Country:	MASSACHUSETTS		
Postal Code:	02110		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	6531804	NULIBRY	
Registration Number:	6413178	BRIDGEBIO	
Registration Number:	6480657	BRIDGEBIO	
Registration Number:	6541355	TRUSELTIQ	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	858-509-4071		
Email:	sdipdocket@pillsburylaw.com		
Correspondent Name:	Michelle L. Mehok		
Address Line 1:	12255 El Camino Real, Suite 300		
Address Line 4:	San Diego, CALIFORNIA 92130		

CH \$115.00 6531804

NAME OF SUBMITTER:	Michelle Mehok
SIGNATURE:	/michelle mehok/
DATE SIGNED:	11/17/2021
Total Attachments: 10 source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page1.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page2.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page3.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page4.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page5.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page6.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page7.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page8.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page9.tif source=BridgeBio - IP Security Agreement 4856-6868-6340 v.2#page10.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement") dated as of November 17, 2021, is made by BRIDGEBIO PHARMA, INC., a Delaware corporation ("Borrower"), ORIGIN BIOSCIENCES, INC., a Delaware corporation ("Origin"), EIDOS THERAPEUTICS, INC., a Delaware corporation ("Eidos"), QED THERAPEUTICS, INC., a Delaware corporation ("QED"), ADRENAS THERAPEUTICS, INC., a Delaware corporation ("Adrenas"), and PHOENIX TISSUE REPAIR, INC., a Delaware corporation ("PTR", and together with Borrower, Origin, Eidos, QED and Adrenas, individually and collectively, "Grantor"), in favor of U.S. Bank National Association, in its capacity as collateral agent (in such capacity, "Agent") for the Secured Parties.

RECITALS

A. Grantor has entered into a Loan and Security Agreement dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the "Loan Agreement") with certain financial institutions party thereto (the "Lenders"), U.S. Bank National Association, in its capacity as administrative agent, and the Agent. All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for the benefit of the Secured Parties a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent for the benefit of the Secured Parties a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyrights, whether published or unpublished, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets and inventions, in each case now or hereafter existing, created, acquired or held;

(c) All letters patent of, or rights corresponding thereto and all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, now or hereafter existing, created, acquired or held, including without limitation the patents and patent applications set forth on Exhibit B attached hereto, and all reissues, divisions, continuations, renewals, extensions, revisions, reexaminations and continuation-in-parts thereof (collectively, the "Patents");

(d) Any trademark (including service marks and trade dress), other source or business identifier, whether registered or not, applications to register and registrations of the same, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit C attached hereto, and the goodwill of the business symbolized by the foregoing (collectively, the "Trademarks");

(e) All mask works for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(f) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(g) All licenses or other rights to use any of the Copyrights, Patents, Trademarks or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(h) All amendments, renewals and extensions of any of the Copyrights, Trademarks, or Patents;
and

(i) All payments on or under of every kind and nature in respect of any or all of the foregoing including without limitation all proceeds and products of the foregoing, and all rights to payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include any trademark application filed on an "intent-to-use" basis until the earlier of the filing of a statement of use with respect thereto or the issuance of a registration therefor.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent (but without obligation), with at least one Business Day's prior written notice to Grantor, to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of New York, and shall have been accepted by Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

7. Electronic Execution of Certain Other Documents. The words "execution," "execute", "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of a signature terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law,


including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Signature page follows.]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:


BRIDGEBIO PHARMA, INC.

By: 
Name: Neil Kumar
Title: President and Chief Executive Officer


ORIGIN BIOSCIENCES, INC.

By: 
Name: Neil Kumar
Title: President


EIDOS THERAPEUTICS, INC.

By: 
Name: Neil Kumar
Title: President and Chief Executive Officer


QED THERAPEUTICS, INC.

By: 
Name: Neil Kumar
Title: President

ADRENAS THERAPEUTICS, INC.

By: 
Name: Neil Kumar
Title: Treasurer

PHOENIX TISSUE REPAIR, INC.

By: 
Name: Neil Kumar
Title: President

AGENT:

U.S. BANK NATIONAL ASSOCIATION, as
Collateral Agent

DocuSigned by:
Alison Nadeau
By: _____
Name: Alison Nadeau
Title: Vice President

[Signature Page to IP Security Agreement]

TRADEMARK
REEL: 007497 FRAME: 0737

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

Company	Title	Application No. Filing Date	(Publication No.) Patent No. Issue Date
QED Therapeutics, Inc.	Methods of treating cholangiocarcinoma	PCT/US2020/034881 5/28/2020	(WO2020243273)
QED Therapeutics, Inc.	Methods of treating urothelial carcinoma	PCT/US2020/035140 5/29/2020	(WO2020243442)
QED Therapeutics, Inc.	Methods of treating a chondroplasia	US63/127,576 12/18/2020	NA
QED Therapeutics, Inc.	Methods of treating cancer	US63/227,761 7/30/2021	NA
Eidos Therapeutics, Inc.	Processes for preparing AG-10, its intermediates, and salts thereof	US15/932,327 2/16/2018	(US20180237396) US10513497 12/24/2019
Eidos Therapeutics, Inc.	Processes for preparing AG-10, its intermediates, and salts thereof	US16/676,931 11/7/2019	(US20200247756) US11078162 8/3/2021
Eidos Therapeutics, Inc.	Processes for preparing AG-10, its intermediates, and salts thereof	US17/350,066 6/17/2021	NA
Eidos Therapeutics, Inc.	Methods of treating TTR amyloidosis using AG10	US16/361,587 3/22/2019	(US20190290616) US11058668 7/13/2021
Eidos Therapeutics, Inc.	Methods of treating TTR amyloidosis using AG10	US17/332,359 5/27/2021	NA
Eidos Therapeutics, Inc.	Formulations of AG-10	US16/542,737 8/16/2019	(US20200054607)
Adrenas Therapeutics, Inc.	Adeno-associated virus gene therapy for 21-hydroxy lase deficiency	US16/962,552 1/17/2019	(US20210277365)
Phoenix Tissue Repair, Inc.	Method for preparing modified collagen outside a host cell	US11/547,822 6/29/2007	(US20080086782) US7932053 4/26/2011
Phoenix Tissue Repair, Inc.	Collagen 7 and related methods	US14/236,403 8/3/2021	(US20150011733) US9676837 6/13/2017
Phoenix Tissue Repair, Inc.	Collagen IV binding assay for the detection of collagen VII	US14/440,958 5/6/2015	(US20160011219) US9733263 8/15/2017
Phoenix Tissue Repair, Inc.	Collagen IV binding assay for the detection of collagen VII	US15/646,303 7/11/2017	(US20180011118) US10921332 2/16/2021
Phoenix Tissue Repair, Inc.	Collagen IV binding assay for the detection of collagen VII	US17/141,586 1/5/2021	(US20210132091)
Phoenix Tissue Repair, Inc.	Administration of recombinant collagen 7 for the treatment of age related disorders	US15/791,577 10/24/2017	(US20180036366)
Phoenix Tissue Repair, Inc.	Collagen 7 compositions and methods of using the same	US16/065,512 6/22/2018	(US20190000912) US10,695,395 6/30/2020

Company	Title	Application No. Filing Date	(Publication No.) Patent No. Issue Date
Phoenix Tissue Repair, Inc.	Colla gen 7 compositions and methods of using the same	US16/875,223 5/15/2020	(US20200316158)
Phoenix Tissue Repair, Inc.	Methods of purifying collagen 7	US16/084,998 9/14/2018	(US20190077845) US10669327 6/2/2020
Phoenix Tissue Repair, Inc.	Recombinant C7 and methods of use	US16/412,192 5/14/2019	(US20190298809)
Origin Biosciences, Inc.	Method for Obtaining Precursor Z a na Use Thereof for the Production of a Means for Therapy of Human Molybdenum Cofactor Deficiency	US11/343,489 1/31/2006	(US20070037250) US7,504,095 3/17/2009
Origin Biosciences, Inc.	Method for Synthesizing Molybdopterin Precursor Z Deriva tives	US14/000,055 2/17/2012	(US20140323726) US9,260,462/16/2016

EXHIBIT C

Trademarks


Owner	Trademark	Application No. / Application Date	Registration No. / Issue Date	Status
Origin Biosciences, Inc.	NULIBRY	90/015,984 6/23/2020	6,531,804 10/19/2021	Registered.
Bridgebio Pharma, Inc.	BRIDGEBIO	90/256,769 10/15/2020	6,413,178 7/6/2021	Registered.
Bridgebio Pharma, Inc.		90/256,677 10/15/2020	6,480,657 9/7/2021	Registered.
QED Therapeutics, Inc.	TRUSELTIQ	90/975,538 10/19/2020	6,541,355 10/26/2021	Registered

EXHIBIT D

Mask Works

None.